WE CLAIM:

- 1. An isolated polynucleotide comprising: a) a polynucleotide having the sequence as shown in SEQ ID NO:1, or its complement; or b) a fragment of said polynucleotide wherein said fragment is: i) at least 10 nucleotides in length; and ii) does not correspond identically in its entirety to any portion of the sequence shown in SEQ ID NOs:2 or 3 or any other known polynucleotide; or c) a polynucleotide that selectively hybridizes to the sequence of SEQ ID NO:1, or said fragment, relative to a known polynucleotide.
- 2. The polynucleotide of claim 1, wherein said polynucleotide that selectively hybridizes to the sequence of SEQ ID NO:1, or said fragment, relative to a known polynucleotide, hybridizes under intermediate stringency conditions.
- 3. The polynucleotide of claim 1, wherein said polynucleotide that selectively hybridizes to the sequence of SEQ ID NO:1, or said fragment, relative to a known polynucleotide, hybridizes under high stringency conditions.
- 4. The polynucleotide according to claim 1 wherein said polynucleotide comprises the sequence as shown in SEQ ID NO:1, or its complement, or said fragment thereof.
- 5. The polynucleotide according to claim 2 wherein said polynucleotide comprises the sequence as shown in SEQ ID NO:1, or its complement, or said fragment thereof.

- 6. The polynucleotide according to any of claim 3 wherein said polynucleotide comprises the sequence as shown in SEQ ID NO:1, or its complement, or said fragment thereof.
- 7. The polynucleotide of claim 1, wherein said polynucleotide consists essentially of the sequence shown in SEQ ID NO:1, or its complement, or a fragment thereof.
- 8. The polynucleotide of claim 2, wherein said polynucleotide consists essentially of the sequence shown in SEQ ID NO:1, or its complement, or a fragment thereof.
- 9. The polynucleotide of claim 3, wherein said polynucleotide consists essentially of the sequence shown in SEQ ID NO:1, or its complement, or a fragment thereof.
- 10. The polynucleotide of claim 4, wherein said polynucleotide consists essentially of the sequence shown in SEQ ID NO:1, or its complement, or a fragment thereof.
- 11. The polynucleotide of claim 5, wherein said polynucleotide consists essentially of the sequence shown in SEQ ID NO:1, or its complement, or a fragment thereof.
- 12. The polynucleotide of claim 6, wherein said polynucleotide consists essentially of the sequence shown in SEQ ID NO:1, or its complement, or a fragment thereof.

- 13. The polynucleotide of claim 1, wherein said fragment is at least 12 nucleotides in length.
- 14. The polynucleotide of claim 2, wherein said fragment is at least 12 nucleotides in length.
- 15. The polynucleotide of claim 3, wherein said fragment is at least 12 nucleotides in length.
- 16. The polynucleotide of claim 1, wherein said fragment is at least 15 nucleotides in length.
- 17. The polynucleotide of claim 2, wherein said fragment is at least 15 nucleotides in length.
- 18. The polynucleotide of claim 3, wherein said fragment is at least 15 nucleotides in length.
- 19. The polynucleotide of claim 1, wherein said fragment is at least 20 nucleotides in length.
- 20. The polynucleotide of claim 2, wherein said fragment is at least 20 nucleotides in length.
- 21. The polynucleotide of claim 3, wherein said fragment is at least 20 nucleotides in length.

- 22. The polynucleotide of claim 1, wherein said fragment is at least 25 nucleotides in length.
- 23. The polynucleotide of claim 2, wherein said fragment is at least 25 nucleotides in length.
- 24. The polynucleotide of claim 3, wherein said fragment is at least 25 nucleotides in length.
- 25. The polynucleotide of claim 1, wherein said fragment is at least 30 nucleotides in length.
- 26. The polynucleotide of claim 2, wherein said fragment is at least 30 nucleotides in length.
- 27. The polynucleotide of claim 3, wherein said fragment is at least 30 nucleotides in length.
- 28. The polynucleotide of claim 1, wherein said fragment is at least 35 nucleotides in length.
- 29. The polynucleotide of claim 2, wherein said fragment is at least 35 nucleotides in length.
- 30. The polynucleotide of claim 3, wherein said fragment is at least 35 nucleotides in length.

- 31. The polynucleotide of claim 1, wherein said fragment is at least 40 nucleotides in length.
- 32. The polynucleotide of claim 2, wherein said fragment is at least 40 nucleotides in length.
- 33. The polynucleotide of claim 3, wherein said fragment is at least 40 nucleotides in length.
- 34. The polynucleotide of claim 1, wherein said fragment is at least 45 nucleotides in length.
- 35. The polynucleotide of claim 2, wherein said fragment is at least 45 nucleotides in length.
- 36. The polynucleotide of claim 3, wherein said fragment is at least 45 nucleotides in length.
- 37. The polynucleotide of claim 1, wherein said fragment is at least 50 nucleotides in length.
- 38. The polynucleotide of claim 2, wherein said fragment is at least 50 nucleotides in length.
- 39. The polynucleotide of claim 3, wherein said fragment is at least 50 nucleotides in length.

- 40. The polynucleotide according to claim 1, wherein said polynucleotide, or its complement or said fragment further comprises a detectable label.
- 41. The polynucleotide according to claim 1, wherein said polynucleotide, or its complement or said fragment is attached to a solid support.
 - 42. A host cell comprising the isolated polynucleotide of claim 1.
 - 43. An isolated polypeptide encoded by the polynucleotide of claim 1.
- 44. An isolated polynucleotide comprising a sequence encoding the polypeptide of claim 43.
- 45. The isolated polynucleotide of claim 44, wherein said polynucleotide is at least 3000 nucleotides.
- 46. An isolated polynucleotide comprising a sequence contained in SEQ ID NO:1 and a sequence contained in SEQ ID NO:2.
- 47. The polynucleotide of claim 46, further comprising a sequence contained in SEQ ID NO:3.
- 48. An isolated polynucleotide comprising a sequence contained in SEQ ID NO:1 and a sequence contained in SEQ ID NO:3.
- 49. An isolated polynucleotide comprising a sequence encoding nacrein of *Pinctada margaritifera*.

- 50. The isolated polynucleotide of claim 49, wherein said polynucleotide is between 1000 and 6000 nucleotides in length.
- 51. The isolated polynucleotide of claim 50, wherein said polynucleotide is between 1000 and 2000 nucleotides in length.
- 52. The isolated polynucleotide of claim 49, wherein said sequence is contained in SEQ ID NO:1.
- 53. A method of determining a condition that permits pearl formation, said method comprising:
 - a) cultivating a pearl oyster under a condition of interest; and
- b) detecting expression of *nacre* gene of the oyster by contacting a sample from the oyster with the polynucleotide of claim 1;

whereby detection of said expression indicates that said condition of interest permits pearl formation.

- 54. The method of claim 53, wherein said pearl oyster is of the species *Pinctada margaritifera*.
- 55. The method of claim 53, wherein said sample from the oyster comprises RNA.
 - 56. The method of claim 55, wherein said sample is from mantle tissue.
- 57. An isolated antibody or antigen binding fragment thereof, that binds to the polypeptide of claim 43, or fragment thereof.

- 58. An isolated antibody that binds to the polypeptide of claim 43, or fragment thereof, said antibody made by the method comprising:
- (a) immunizing a host animal with a composition comprising said polypeptide, or fragment thereof; and
- (b) collecting cells from said host expressing antibodies against the polypeptide, or fragment thereof.
- 59. An isolated antibody that binds to the polypeptide of claim 43, or fragment thereof, said antibody made by the method comprising:
- (a) providing a cell line producing an antibody, wherein said antibody binds to said polypeptide, or fragment thereof; and
- (b) culturing said cell line under conditions wherein said antibodies are produced.
- 60. A method of determining a condition that permits pearl formation, said method comprising:
 - a) cultivating a pearl oyster under a condition of interest; and
- b) detecting expression of *nacre* gene of the oyster by contacting a sample from the oyster with the antibody of claim 57;

whereby detection of said expression indicates that said condition of interest permits pearl formation.

- 61. A method of determining a condition that permits pearl formation, said method comprising:
 - a) cultivating a pearl oyster under a condition of interest; and
- b) detecting expression of *nacre* gene of the oyster by contacting a sample from the oyster with the antibody of claim 58;

whereby detection of said expression indicates that said condition of interest permits pearl formation.

- 62. A method of determining a condition that permits pearl formation, said method comprising:
 - a) cultivating a pearl oyster under a condition of interest; and
- b) detecting expression of *nacre* gene of the oyster by contacting a sample from the oyster with the antibody of claim 59;

whereby detection of said expression indicates that said condition of interest permits pearl formation.

- 63. The method of claim 60, wherein said pearl oyster is of the species *Pinctada margaritifera*.
- 64. The method of claim 60, wherein said sample from the oyster comprises polypeptides.
 - 65. The method of claim 64, wherein said sample is from mantle tissue.
- 66. A method of detecting a nacrein-expressing oyster, said method comprising:
- (a) contacting a sample from said oyster with the polynucleotide of claim 1; and
 - (b) detecting hybridization of said polynucleotide to the sample.
- 67. A method of detecting a nacrein-expressing oyster, said method comprising:
 - (a) contacting a sample from said oyster with the antibody of claim 57; and

- (b) detecting binding of said antibody to the sample.
- 68. A method of quantifying *nacre* gene expression in a sample, said method comprising:
 - (a) contacting said sample with the polynucleotide of claim 1;
 - (b) detecting hybridization of said polynucleotide to said sample;
- (c) comparing the amount of the hybridization of step (b) with the amount of hybridization of said polynucleotide to a reference polynucleotide.
- 69. The method of claim 68, wherein said sample is obtained from a pearl oyster.
 - 70. A method of quantifying nacrein in a sample, said method comprising:
 - (a) contacting said sample with the antibody of claim 57;
 - (b) detecting binding of said antibody to said sample;
- (c) comparing the amount of the binding of step (b) with the amount of binding of said antibody to a reference polypeptide.
- 71. The method of claim 70, wherein said sample is obtained from a pearl oyster.
- 72. An isolated polypeptide according to claim 43, comprising amino acids 81-194 of SEQ ID NO:4.
- 73. An isolated polypeptide according to claim 43, comprising amino acids 520-609 of SEQ ID NO:4.

- 74. An isolated polypeptide according to claim 43, comprising amino acids 81-194 and 520-609 of SEQ ID NO:4.
- 75. An isolated polynucleotide according to claim 44, comprising a sequence encoding amino acids 81-194 of SEQ ID NO:4.
- 76. An isolated polynucleotide according to claim 44, comprising a sequence encoding amino acids 520-609 of SEQ ID NO:4.
- 77. An isolated polynucleotide according to claim 44, comprising a sequence encoding amino acids 81-194 and 520-609 of SEQ ID NO:4.